Myriad GeneticsSTU:MYD +0.72%53 Quick Ratio is 2.19 as of Mar. 2026, which is 1% above its 10-year median of 2.16. GuruFocus rates STU:MYD with a GF Score™ of 53/100 and a GF Value™ of €13.06 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Myriad Genetics ranks better than 54.67% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Myriad Genetics's quick ratio for the quarter that ended in Mar. 2026 was 2.19.
Myriad Genetics has a quick ratio of 2.19. It generally indicates good short-term financial strength.
The historical rank and industry rank for Myriad Genetics's Quick Ratio or its related term are showing as below:
STU:MYD'
s Quick Ratio Range Over the Past 10 Years
Min: 0.98 Med: 2.16 Max: 3.82
Current: 2.19
During the past 13 years, Myriad Genetics's highest Quick Ratio was 3.82. The lowest was 0.98. And the median was 2.16.
STU:MYD's Quick Ratio is ranked better than 54.67% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.69
vs STU:MYD: 2.19
Myriad Genetics (STU:MYD) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Myriad Genetics Quick Ratio Related Terms
Myriad Genetics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: Quick Ratio Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Myriad Genetics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a Quick Ratio of 2.19 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Myriad Genetics and its competitors. This is near median its historical median of 2.16. Over the past decade, Myriad Genetics' Quick Ratio has ranged from 0.98 to 3.82. According to the industry distribution chart, Myriad Genetics ranks #97 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 45.3%.
Is Myriad Genetics' Quick Ratio too high?
Myriad Genetics' current Quick Ratio of 2.19 is near median its 10-year median of 2.16. Over the past 10 years, this metric has ranged from a low of 0.98 to a high of 3.82. The Medical Diagnostics & Research industry median Quick Ratio is 1.69. Myriad Genetics' value of 2.19 is 29.6% above this industry median. Based on the distribution chart, Myriad Genetics ranks #97 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Quick Ratio compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #97 out of 214 companies for Quick Ratio. This puts Myriad Genetics in the upper half of its industry. The industry median Quick Ratio is 1.69. Myriad Genetics' value of 2.19 is 29.6% above this benchmark. Historically, Myriad Genetics' own Quick Ratio has ranged from 0.98 to 3.82 over the past decade. While the company's 10-year median is 2.16 vs. the industry median of 1.69, Myriad Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.69, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current Quick Ratio of 2.19 is 29.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Quick Ratio is 2.19, which is near median its own 10-year median of 2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.06, compared to a current price of €5.05 — trading 61.3% below its estimated fair value. The current Quick Ratio is 2.19, which is near median its 10-year median of 2.16 and 29.6% above the Medical Diagnostics & Research industry median of 1.69. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Quick Ratio is 2.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €5.05 is trading 61.3% below its estimated GF Value™ of €13.06.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Quick Ratio: 2.19 (near median its 10-year median of 2.16)
GF Value™: €13.06 vs. price of €5.05 (61.3% below fair value)
Industry Position: 29.6% above the Medical Diagnostics & Research median (#97 of 214)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score
Get the complete analysis for STU:MYD
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
